Literature DB >> 19590529

Downregulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1alpha.

K Küster1, A Koschel, N Rohwer, A Fischer, B Wiedenmann, M Anders.   

Abstract

Loss of the coxsackie and adenovirus receptor (CAR) has been found in various human cancers. Underlying mechanisms, however, are still poorly understood. Therefore, the objective of this study was to investigate the function of hypoxia, a ubiquitous phenomenon in carcinomas, in CAR regulation. In our approach, hypoxia and treatment with cobalt-(II)-chloride (CoCl(2)) induced a downregulation of CAR protein and mRNA expression, as well as a suppression of CAR gene promoter activity in AGS (gastric), SW480 (colon) and PC3 (prostate) cancer cells. In line with these findings we noted a decreased adenoviral uptake under hypoxic conditions. Aiming to further elucidate the molecular basis of this observation, a full-length hypoxia-inducible factor-1alpha (HIF-1alpha) cDNA was ectopically overexpressed in the AGS cell line diminishing CAR expression and CAR gene promoter activity. In line with these findings, exposure of HIF-1alpha-deficient AGS cells to hypoxia did not alter CAR mRNA expression level. On the basis of these data, it may be suggested that loss of CAR in human cancer cell lines under hypoxic conditions occurs in an HIF-1alpha-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590529     DOI: 10.1038/cgt.2009.49

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  16 in total

1.  Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.

Authors:  Kaylin M McMahon; R Kannan Mutharasan; Sushant Tripathy; Dorina Veliceasa; Mariana Bobeica; Dale K Shumaker; Andrea J Luthi; Brian T Helfand; Hossein Ardehali; Chad A Mirkin; Olga Volpert; C Shad Thaxton
Journal:  Nano Lett       Date:  2011-02-14       Impact factor: 11.189

2.  Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy.

Authors:  Michael J Oneal; Miguel A Trujillo; Julia Davydova; Samantha McDonough; Masato Yamamoto; John C Morris
Journal:  Hum Gene Ther       Date:  2012-08-22       Impact factor: 5.695

3.  Association of Wnt2 and sFRP4 expression in the third trimester placenta in women with severe preeclampsia.

Authors:  Zhan Zhang; Lin Zhang; Linlin Zhang; Liting Jia; Peng Wang; Yan Gao
Journal:  Reprod Sci       Date:  2013-01-15       Impact factor: 3.060

4.  Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC).

Authors:  Dong Chen; Ayesha Siddiq; Luni Emdad; Devaraja Rajasekaran; Rachel Gredler; Xue-Ning Shen; Prasanna K Santhekadur; Jyoti Srivastava; Chadia L Robertson; Igor Dmitriev; Elena A Kashentseva; David T Curiel; Paul B Fisher; Devanand Sarkar
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

5.  A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.

Authors:  M K Magnusson; R Kraaij; R M Leadley; C M A De Ridder; W M van Weerden; K A J Van Schie; M Van der Kroeg; R C Hoeben; N J Maitland; L Lindholm
Journal:  Hum Gene Ther       Date:  2011-10-12       Impact factor: 5.695

6.  The hTERT promoter enhances the antitumor activity of an oncolytic adenovirus under a hypoxic microenvironment.

Authors:  Yuuri Hashimoto; Hiroshi Tazawa; Fuminori Teraishi; Toru Kojima; Yuichi Watanabe; Futoshi Uno; Shuya Yano; Yasuo Urata; Shunsuke Kagawa; Toshiyoshi Fujiwara
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

7.  ZEB1 limits adenoviral infectability by transcriptionally repressing the coxsackie virus and adenovirus receptor.

Authors:  Markus D Lacher; Marisa Shiina; Peter Chang; Debora Keller; Maarit I Tiirikainen; W Michael Korn
Journal:  Mol Cancer       Date:  2011-07-27       Impact factor: 27.401

8.  Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis.

Authors:  M Reeh; M Bockhorn; D Görgens; M Vieth; T Hoffmann; R Simon; J R Izbicki; G Sauter; U Schumacher; M Anders
Journal:  Br J Cancer       Date:  2013-09-10       Impact factor: 7.640

9.  Characterization of an Oncolytic Adenovirus Vector Constructed to Target the cMet Receptor.

Authors:  Hany I Sakr; David T Coleman; James A Cardelli; J Michael Mathis
Journal:  Oncolytic Virother       Date:  2015

10.  Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5NULL-A20.

Authors:  James A Davies; Gareth Marlow; Hanni K Uusi-Kerttula; Gillian Seaton; Luke Piggott; Luned M Badder; Richard W E Clarkson; John D Chester; Alan L Parker
Journal:  Viruses       Date:  2021-05-08       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.